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of patients
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Amyotrophic lateral sclerosis (ALS) is characterized by the progressive loss of motor neurons followed 
by muscle weakness, paralysis and death. The disease progression is extremely variable among 
patients, and reliable prognostic markers have not been identified. The aim of the study was to 
functionally characterize selected genes and microRNAs acting in the skeletal muscle of ALS patients, 
taking into account the duration and evolution of the disease, in order to obtain information regarding 
the muscle response to ALS progression. This prospective, longitudinal study enrolled 14 ALS patients 
and 24 age- and sex-matched healthy controls. Gene expression and histological analysis indicated an 
increase of MIR208B and MIR499 levels and the predominance of slow fibres, respectively, in the muscles 
of patients with a slower disease progression. A decreased expression of MIR206 and increased levels 
of HDAC4, during the progression of the disease were also observed. Taken together, our data suggest 
that the molecular signalling that regulates re-innervation and muscle regeneration is hampered 
during the progression of skeletal muscle impairment in ALS. This could provide precious hints towards 
defining prognostic protocols, and designing novel tailored therapeutic approaches, to improve ALS 
patients’ care and delay disease progression.
In amyotrophic lateral sclerosis (ALS) motor neuron degeneration leads to muscle atrophy, with death usually 
occurring as a result of respiratory failure, in 3–5 years. However, the survival time is extremely variable; some 
patients can live beyond 10 years since diagnosis, while others undergo a very rapid disease progression.
The first disease event, observed in both patients and transgenic mouse models, is the destruction of the neu-
romuscular junction. This led to formulate the “dying-back” hypothesis, according to which defects of neuromus-
cular functions occur before motor neurons (MNs) anomalies1, 2. Several pieces of evidence indeed indicate that, 
before the clinical onset and during the disease progression, the skeletal muscles of ALS patients undergo futile 
cycles of denervation and re-innervation, along with MNs degeneration3. When the MNs start degenerating, 
surrounding axons sprout from surviving neurons to re-innervate the muscle fibres and compensate the missing 
synapses. Muscle fibres are broadly classified into slow-twitch (type I) and fast-twitch (type II) based on the myo-
sin heavy chain (MHC) gene expression and on the metabolic path (oxidative/glycolytic) used for ATP produc-
tion4. Since all muscle fibres in a motor unit (MU) are of the same type, when the MUs enlarge, the skeletal muscle 
is reorganized in clustering of fibres of the same metabolic type (fibre type grouping). Ultimately these MUs 
lose their innervation and start undergoing atrophy. Type I and type II fibres are innervated by different MNs; 
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interestingly both in ALS patients and in the SOD1G85R transgenic mouse model, the number of large-calibre 
axons (innervating type II fibres) in the spinal cord is significantly lower than in controls, whereas the number 
of small-calibre axons (innervating type I fibres) is preserved5, 6. It is noteworthy that specific muscles (e.g. the 
extrinsic eye muscles and the bladder detrusor muscle) are selectively spared in ALS, suggesting that the corre-
sponding MNs, in charge of their innervation, are relatively resistant to neurodegeneration. Consistently with 
these observations, in the SOD1G93A mouse, muscles enriched in slow-twitch fibres undergo denervation at 
later stages, compared with those housing more fast-twitch fibres7. A strategy designed to target early muscle 
denervation could plausibly represent a valuable tool to delay disease progression.
Preclinical evidence obtained in the SOD1G93A mouse model indicated that the histone deacetylase 
4 (HDAC4) increases in the skeletal muscle during the denervation process, and constitutively blocks the 
re-innervation signalling8. In turn, denervation induces the up-regulation of MIR206, which promotes 
re-innervation by suppressing muscular HDAC4 protein levels. Accordingly, in the SOD1G93A mouse model, 
suppression of the MIR206-dependent HDAC4 down-regulation accelerates disease progression, whereas 
MIR206 over-expression boosts the regeneration of neuromuscular synapses after acute nerve injury8. HDAC4 
inhibition through MIR206 has been, indeed, proposed as a reasonable therapeutic strategy in ALS. In ALS 
patients, the muscular HDAC4 levels positively correlate with the disease progression and severity, thus support-
ing its role also in human tissues9. Taken together, these observations suggest that the skeletal muscle, and the 
local molecular signalling, may represent valuable therapeutic targets in ALS10.
The aim of this study was hence to define the molecular signalling acting in the skeletal muscle of patients 
during the disease progression, in the attempt to identify suitable molecular markers implicated in skeletal mus-
cle resistance to denervation and atrophy, and in the modulation of muscle re-innervation during early stages of 
ALS. To address these issues, we have focused on: 1. the MIR206/HDAC4 interplay underlying the human skeletal 
muscle response during ALS evolution; 2. the structural changes that occur during the disease progression in the 
muscle tissue of ALS patients, stratified per relevant clinical variables. The functional role of MIR206 has been 
further validated in vitro, using primary cultures of satellite cells isolated from the skeletal muscle of ALS patients 
and controls.
Results
Clinical stratification of ALS patients. Based on the available information (see Table 1) about the clinical 
evolution of the disease, ALS patients were categorized into two groups: ‘slow’, i.e. ≥4 years of duration of disease 
without requiring respiratory supports (N = 6), and ‘rapid’ (N = 5), i.e. <4 years of disease progression without 
respiratory support or death occurring <4 years from symptoms onset. The average disease duration significantly 
changed between the two groups (P = 0.0269), being 66.5 months (range 48–134) and 25 months (range 12–39), 
in the slow and rapid group, respectively. Patients in the slow group showed a significantly reduced age of onset 
(mean age = 50.5 years), compared with those in the rapid group (mean age = 65 years, P = 0.0466). ALS patients 
were then alternatively stratified based on the duration of the disease at biopsy (i.e. time passed since the onset of 
symptoms until the muscle biopsy). According to this criterion, patients were stratified into ‘early’, i.e. less than 
one year (N = 4) and ‘late’, i.e. more than one year (N = 9).
Gene and protein expression in skeletal muscle tissues. Eight genes and eleven microRNAs involved 
















































1 F 50 NA Spinal Sporadic NA NA Deltoid F = 0 NA 134 (T) slow Negative x x x
2 F 70 71 Spinal Sporadic 13 late Quadriceps F = 5 33/48 30 (D) rapid Negative x x x
3 M 69 71 Spinal Sporadic 18 late Deltoid NA NA 16 (T) rapid Negative x x x
4 M 63 63 Spinal Sporadic 7 early Quadriceps F = 5 36/48 28 (D) rapid Negative x x
5 M 65 65 Spinal Sporadic 6 early Deltoid F = 3 42/48 59 (D) slow Negative x x
6 M 43 43 Spinal Sporadic 9 early NA NA 37/48 14 (LF) NA Negative x x
7 F 59 59 Spinal Sporadic 10 early Quadriceps F = 5 42/48 58 (D) slow C9ORF72 x x x
8 F 54 55 Bulbar Sporadic 19 late Deltoid F = 5 43/48 39 (D) rapid Negative x x x
9 M 50 53 Spinal Familial 28 late Quadriceps F = 5 41/48 48 (A) slow Negative x x x x x
10 F 28 30 Spinal Sporadic 26 late Quadriceps F = 5 41/48 48 (A) slow Negative x x x x
11 M 69 70 Bulbar Sporadic 13 late Quadriceps F = 4 23/48 12 (T) rapid Negative x x x x x
12 F 51 54 Spinal Sporadic 36 late Quadriceps NA NA 52 (A) slow Negative x x x
13 F 55 56 Spinal Familial 14 late Quadriceps F = 3 43/48 25 (A) NA C9ORF72 x x x
14 F 57 57 Spinal Familial 13 late Quadriceps F = 5 46/48 18 (A) NA SOD1 L84F x x x x
Table 1. Detailed ALS patient and specimen data. *The MRC score was referred to the muscle at biopsy 
and ranged from 0 (no visible movement) to 5 (normal muscle strength). **ALSFRS-R scores, at the time of 
muscle biopsy, ranged from 0 (total disability) to 48 (no disability). F = female; M = male; NA = not available; 
T = invasive mechanical ventilation by tracheotomy; D = dead; LF = lost at follow-up; A = alive.
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MYOG, MYOD1, PAX7 and PAX3 transcript levels resulted significantly increased in ALS patients compared with 
controls (Fig. 1A). Consistently, also HDAC4 protein levels increased in ALS samples compared with controls 
(Fig. 1B). None of the analyzed microRNAs showed a significant difference in expression levels, between patients 
and controls (Supplementary Fig. 1).
Thereafter, gene expression data were also analyzed considering patients’ stratification. Results of differen-
tial gene expression according to the disease duration (i.e. patients categorized into slow and rapid groups) are 
displayed in Fig. 2A and B. In particular, HDAC4, MYOD1, PAX3 and MYF5 were up-regulated only in the slow 
group, compared with controls, while MYOG and PAX7 increased in both groups. FGFBP1 levels were very var-
iable, reaching a significant up-regulation over controls only in the rapid group. Among the tested microRNAs, 
MIR133A, MIR29C, MIR9 and MIR208B were significantly up-regulated in the ALS slow group, whereas MIR1 
and MIR208B expression was lower in the rapid group, than in controls. Interestingly, the expression of MIR499, 
MIR29C and MIR208B was significantly lower in the ALS rapid group than in the slow one.
Figure 1. Expression profile of skeletal muscle biopsies of ALS patients and controls. (A) The diagrams plot 
the relative transcript levels of the genes analyzed by reverse qPCR, calculated according to the 2−ΔΔCt method, 
using ACTB as housekeeping gene for normalization. All data were expressed as mean fold change ± SD across 
replicates, with control values set to 1. Unpaired t-test was used to detect the statistical significance between ALS 
and controls values; *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001. (B) Quantitative analysis of western blot for HDAC4 
protein expression in muscle specimens of ALS patients and controls. Relative protein content was determined 
by optical density of the HDAC4 bands normalized to stain free gel.
Figure 2. Molecular evaluation on the basis of the clinical stratification of ALS patients. Relative expression 
trend of genes (A) and microRNAs (B) in slow (with ≥4 years of disease progression without requiring 
respiratory support) and rapid (with <4 years of disease progression) ALS groups compared with controls. 
Relative expression trend of genes (C) and microRNAs (D) of early (less than one year from symptom onset to 
muscle biopsy) and late (more than one year from symptom onset to muscle biopsy) ALS groups and controls. 
All data were expressed as mean fold change ± SD across replicates, with control values set to 1. Unpaired 
t-test was used to detect the statistical significance between ALS and controls values; *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001.
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We then comparatively analyzed gene expression data in patients stratified based on disease duration at biopsy 
(i.e. within early and late patients’ groups). The results showed that, within one year from the onset of symp-
toms, the genes involved in regeneration (PAX7 and PAX3) and re-innervation (HDAC4, MYOG, MYOD1 and 
FGFBP1) pathways are activated in the affected skeletal muscle (Fig. 2C). The expression of MIR206, MIR155, 
MIR23A, MIR133A, MIR133B, MIR29C and MIR9 increased only in the early stage group, compared with con-
trols (Fig. 2D). MIR206 and MIR9 expression levels also significantly changed between the early and the late 
groups. Interestingly, MIR206 levels inversely correlated with the time from symptoms onset to muscle biopsy 
(R = −0.8309, P = 0.0106) (Fig. 3A). Conversely, MIR9 expression did not correlate with the progression of the 
disease (data not shown). Also, we did not find any statistically significant correlation between either of HDAC4 
transcript (Fig. 3B) and protein levels and the disease duration (data not shown).
Gene expression during in vitro myogenic differentiation. Satellite cells derived from ALS patients 
and controls were induced towards myogenic differentiation in vitro for 14 days. Thereafter, the expression of the 
genes involved in the myogenic differentiation process (HDAC4, MYOG, MYOD1, MEF2C, MYF5, PAX7 and 
PAX3) was analyzed in time course, after 1 and 2 weeks of induction. The expression trends, during in vitro dif-
ferentiation, were very similar in ALS and controls for all tested genes (Supplementary Fig. 2). When comparing 
the gene expression levels between cells from ALS patients and controls at each time point (i.e. expression analysis 
between matched ALS and control cultures at each single time point), we found significant differences in selected 
genes: MYOD1, PAX7, PAX3 and MYF5 showed increased levels in ALS patients, compared with controls, while 
HDAC4, MYOG and MEF2C levels were lower in the ALS group than in controls (Fig. 4A). PAX7, MYOD1 and 
MYF5 represent early markers of stem cell activation, while MYOG, MEF2C and HDAC4 are known to increase 
in later stages of the differentiation process (Fig. 4B). Therefore, the expression profiles observed in our sample 
seemed to suggest that the myogenic differentiation slows down in ALS cells compared with controls.
Functional characterization of MIR206 in cells. In order to validate the functional effect of MIR206 
in the myogenic process, we performed a MIR206 mimic assay in ALS and control satellite cells. The mimic 
construct was transfected in cells during the administration of myogenic medium for 1 week. The expression of 
the tested targets (HDAC4, PAX7 and PAX3 genes) and of the genes involved in the MIR206/HDAC4 interplay 
(MYOD1, MEF2C, MYF5 and FGFBP1) was significantly reduced upon the MIR206 mimic treatment in control 
Figure 3. Correlation and expression analysis based on MIR206 expression levels. Pearson’s correlation test of 
MIR206 (A) and HDAC4 (B) relative expression levels of ALS patients with the time from symptoms onset to 
muscle biopsy.
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cells (Fig. 5A). In ALS cell cultures, only MYOD1 levels significantly decreased after MIR206 mimic, while MYOG 
and FGFBP1 showed increased expression trends (Fig. 5B). HDAC4 protein levels were significantly reduced after 
MIR206 mimic treatment, in both ALS and controls (Fig. 5C). Therefore, although HDAC4 transcript levels did 
not change, MIR206 over-expression was apparently able to modulate protein expression also in ALS cells, during 
the course of myogenic differentiation.
Morphological assessment of skeletal muscles. The down-regulation of MIR208B and MIR499 
observed in the rapid-versus-slow progression groups, is known to be associated with fibre type switch in the skel-
etal muscles11. This prompted us to perform the morphological assessment comparing patients in the rapid group 
Figure 4. ALS and controls cell cultures display a different response to myogenic induction. (A) Relative 
transcript levels of the genes involved in proliferation, activation and differentiation processes, analyzed in 
time course. All data were expressed as mean fold change ± SD across replicates, with control values set to 1. 
Unpaired t-test was used to detect the statistical significance; *P ≤ 0.05. (B) Scheme of the putative molecular 
signature of myogenic conversion: the expression of differentiation markers increase while satellite cells turn 
into terminally differentiated myocytes, at the start of the myogenic induction and after 1 and 2 weeks.
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(N = 5) with those in the slow group (N = 3). To define the distribution of fibre types I and II, and the percentage 
of atrophic fibres, we performed histological analysis on skeletal muscle biopsies from quadriceps and deltoid 
muscles of ALS patients (Fig. 6A).
The results of fibre quantification (Fig. 6B and Supplementary Table 1) showed that the percentage of type 
I fibres is greater in the slow than in the rapid group (mean 48,38–25,84% respectively, P = 0.0421). The per-
centage of type II fibres did not change between the groups. Interestingly, in the rapid group the percentage of 
atrophic fibres inversely correlated with the amount of both types of fibres (RI fibres = −0.9548, P = 0.0115; RII 
fibres = −0.947, P = 0.0145), whereas in the slow group, it inversely correlated only with the amount of type II fibres 
(RII fibres = −0,864, though this correlation is not significant). Our data indicated also that the percentage of type II 
fibres in the rapid group is lower than the percentage of type I fibres, the latter being mainly spared from atrophy 
in the slow group, while preferentially damaged in the rapid one.
Discussion
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, for which, to date, no effective therapy 
has been found. The mean survival of patients from symptom onset is 3 to 5 years12, but the disease progression 
and severity are extremely variable. Some patients have a milder and protracted course of illness, while others 
need respiratory support as early as within one year from the onset. An exact estimate of the rate of long surviving 
patients is not available; recent population-based studies have reported a 5-years survival rate ranging from 22 to 
52% of patients13. Several variables, including predominance of upper motor neuron signs, spinal onset, male sex 
and younger age, have been already analyzed to establish associations with a longer life expectancy, but the results 
are not univocal. Based on the extant literature, the age and site of symptoms’ onset are the strongest prognostic 
predictors. In fact, in several population-based studies, younger age at onset has been found to predict long-term 
survival of ALS patients, whereas bulbar onset has been invariably identified as a negative prognostic predictor13.
In this study, we have used an in vitro model to investigate the response of the skeletal muscle during the 
disease progression. We have specifically found that the skeletal muscle of ALS patients showing a longer sur-
vival period expresses higher levels of microRNAs involved in the regulation of the slow-to-fast fibre type switch 
profile, compared with patients with a rapid disease progression. Moreover, we observed that the expression of 
molecular markers of skeletal muscle denervation tends to decrease within the first year since clinical onset.
In particular, we demonstrated that genes encoding myogenic regulatory factors (HDAC4, MYOG, MYOD, 
PAX3 and PAX7) are consistently up-regulated in the skeletal muscle of ALS patients, more intensely within the 
first year since the onset of symptoms. These data may suggest that during the early stages of ALS, the molecular 
signalling implied in muscular regeneration is activated. In addition, the expression of MIR206 and MIR9 was 
significantly different between patients in early and late stages of disease progression. These data further indi-
cated that the skeletal muscle of ALS patients activates an early response to denervation, which decreases over 
time at later stages. Also HDAC4 activation seemed to occur within one year from symptoms’ onset. HDAC4 
Figure 5. MIR206 mimic effects in primary cultures of ALS patients and controls. Controls and ALS cultures 
induced along myogenic differentiation, were transfected with MIR206 mimic for 1 week. The graphs show 
the effects of MIR206 over-expression on the expression of the genes involved in regeneration and innervation 
pathways, in controls (A) and ALS (B) cultures. All data are expressed as mean fold change ± SD across 
replicates, with mock treated cells values set to 1. Unpaired t-test was used to detect the statistical significance 
between samples; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (C) Quantitative analysis of western blot for HDAC4 
protein expression in ALS patients and controls cultures treated upon MIR206 over-expression. HDAC4 relative 
protein content was determined by optical density of the HDAC4 bands normalized to stain free gel.
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up-regulation has been already described as a response to skeletal muscle denervation in the SOD1G93A ALS 
mouse model, in which it induces MYOG up-regulation. This, on turn, triggers the molecular cascade associated 
with muscular atrophy8. MYOG activates, indeed, the transcription of MIR206, establishing a negative feedback 
loop able to inhibit HDAC4. Finally, HDAC4 inhibition induces the expression of FGFBP1, which promotes 
re-innervation and regeneration of the neuromuscular junction8. In humans HDAC4 is up-regulated in ALS 
patients featuring a rapidly progressive disease compared with long-term survivors, while MIR206 is up-regulated 
in both patient groups, although its levels do not correlate with the disease progression9. Interestingly, our data 
indicated that HDAC4 transcript and protein are increased in all patients, regardless of the time passed since the 
onset of symptoms at the time of muscle biopsy. Apparently, HDAC4 levels grow up until six months of disease 
duration and then it reaches a constant trend. In the early stage of the disease, also FGFBP1 and MYOG are acti-
vated demonstrating that the pathway described in mice8 is active also in humans. However, after one year from 
Figure 6. Histological analysis of ALS patients. (A) Representative images that showed the pattern of muscle 
fibre atrophy, with different fibre types stained differently. Differences in the fibre type ratio is detected between 
ALS patients in the slow group (left panels) and those in the rapid group (right panels). The hematoxylin-
eosin staining (top panels) and the ATPase staining (bottom panels) highlighted the atrophy pattern and fibre 
composition. (B) The bar-graph illustrates the percentage of type I, type II and atrophic fibres in the skeletal 
muscle sections of rapid and slow ALS patients. An overall number of >1000 muscle fibres was counted for each 
assessed patient.
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symptoms onset, FGFBP1 and MIR206 levels decrease, which may cause the muscle to be less prone to react to 
denervation and muscular atrophy. Indeed, our data indicated that MIR206 up-regulation is detectable in the 
affected muscle within one year from the clinical onset, and becomes less evident as the disease progresses to a 
later stage.
In our study, the intracellular levels of MIR206 could be efficiently modulated in ALS muscle satellite cells, in 
which MIR206 over-expression is associated with HDAC4 protein down-regulation. Indeed, upon mimicking 
MIR206 in cells, the expression of transcription factors downstream to HDAC4 decreased.
Our data also showed an up-regulation of MIR208B and MIR499 in the skeletal muscles of patients with a 
slow progression of the disease. MIR208B and MIR499 play redundant roles in the specification of muscle fibre 
identity, by activating slow-, and repressing fast-myofibre molecular programs11. MIR208B and MIR499 genes are 
encoded within introns of two type I Myosin Heavy Chain (MyHC) genes (MYH7 gene coding for MyHC-β/slow 
and MYH7B gene coding for MyHC-slow tonic, respectively). Double knockout mice for both miRNAs displayed 
a marked slow-to-fast switch in fibre type profile and MyHC expression, while muscle-specific over-expression 
of MIR499 led to a complete fast-to-slow switch in the MyHC profile11. On this regard, the histological analysis 
of muscle biopsies of ALS patients showed that type I fibres in the slow group are mainly spared from atrophy, 
while being preferentially damaged in the rapid one. Slow and fast fibres in the skeletal muscle are innervated by 
different MNs. Interestingly, both in ALS patients and in the SOD1G85R transgenic mouse model, the axons of 
neurons innervating type I fibres are selectively spared5, 6. Moreover, a recent study on the SOD1G93A mouse, 
demonstrated the occurrence of a fast-to-slow shift in the fibre type composition, at later stages of the disease14. 
Altogether these data suggested that the muscle fibres and the corresponding MNs collaborate to counteract skel-
etal muscle atrophy during early stages of ALS pathogenesis. This may lead to a slow muscle phenotype in long 
surviving patients, similarly to what occurs in mutant mice at final stages. The intrinsic properties of muscle cells, 
together with the pattern of impulse activity imposed on muscle fibres, play a dominant role in determining fibre 
type composition in regenerating muscles, which, in turn, respond differently to the same stimulation pattern15.
The skeletal muscle can regenerate after injury, due to the activation and proliferation of satellite cells. 
Normally quiescent, these myogenic precursors are activated during damage and start expressing specific myo-
genic transcription factors16. In line with previous evidence in the literature17, 18, our data indicated that satellite 
cells from ALS patients tend to respond slower to in vitro myogenic induction. These cells displayed opposite 
expression trends between genes associated with regeneration and early differentiation (PAX3 and PAX7), and 
markers of terminal differentiation (MYOG and MEF2C). This may suggest that, as a result, the skeletal muscle 
could not be able to effectively repair and regenerate, leading to severe muscle atrophy and weakness. The muscle 
regeneration process is indeed hampered or, at least, delayed in ALS patients. Different studies performed on 
ALS satellite cultures, already demonstrated that ALS-derived myoblasts are unable to fully differentiate into 
myotubes17, 18, and that myotubes from ALS patients have decreased levels of the MYOG protein18.
In this scenario, MIR206 seems to play an essential role during the pathogenesis of ALS skeletal muscle 
impairment and regeneration, by regulating PAX7, PAX3 and HDAC4 levels, hence altering the balance between 
cell proliferation and differentiation19.
In conclusion, our study allowed identifying a complex molecular network acting in the skeletal muscle of ALS 
patients, plausibly affecting both re-innervation and muscle regeneration. Re-innervation and muscle repair are 
inherently inter-dependent processes, as the skeletal muscle plays an active role in maintaining neuromuscular 
junction stability. MIR206 seems to link these processes, as its over-expression enhances the muscle regenerative 
potential during ALS progression8. An over-expression of MIR208B and MIR499 could instead make the skeletal 
muscle more resistant to denervation and ALS progression (Fig. 7).
Targeting muscular microRNAs could represent a valuable strategy aimed at restoring the molecular pathways 
improving motor performance and enhancing the production of growth factors (such as FGFBP1) able to facili-
tate the re-innervation process and delay ALS progression.
Materials and Methods
Patients and specimens. 14 ALS patients and 24 age- and sex-matched healthy controls have been enrolled 
in this study, which was approved by the ethics committee of the Università Cattolica del Sacro Cuore [proto-
col P/774/CE/2012]. All the following experiments were performed in accordance with relevant guidelines and 
regulations. All patients provided a written informed consent prior to all investigations. ALS diagnosis was per-
formed according to the revised El Escorial criteria. The functional impairment was assessed using the revised 
ALS Functional Rating Scale (ALSFRS-R), which rates the performance of activities of daily living and scores 
from 0 (total disability) to 48 (no disability), based on a 12-item scale. Muscle strength was measured by manual 
muscle testing according to the grading system proposed by the Medical Research Council (MRC score), ranging 
from 0 (no visible movement) to 5 (normal muscle strength).
Detailed clinical data of ALS patients are provided in Table 1. Briefly, the ALS sample included six males and 
eight females, aged 30-to-71 (average age: 57 ± 12) years at biopsy. All patients were Caucasian. Genetic testing 
was performed to assess the presence of mutations in the ALS-associated SOD1, TARDBP, FUS, ANG, ATXN2 
and C9orf72 genes. Three patients carried SOD1 and C9orf72 mutations.
Age- and sex- matched control individuals were selected among patients undergoing orthopaedic surgery for 
traumatic injury and without positive history for muscle weakness, nor any neurological disorders.
A skeletal muscle specimen was collected through an open biopsy performed either in the deltoid muscle 
(four ALS patients) or in the quadriceps (nine ALS patients). Upon collection, the tissue specimens were stored in 
liquid nitrogen for histological analyses, in Allprotect tissue reagent (Qiagen) for protein isolation, in RNA later 
(Qiagen) for RNA extraction, and in culture medium for cells isolation.
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Cell cultures. Primary satellite cells were isolated from muscle specimens (six patients and six controls), 
through enzymatic digestion. Briefly the tissue was mechanically fragmented and digested with collagenase/dis-
pase (Roche). The tissue homogenate was then separated through a 40 µm mesh filter and seeded into culture 
plates. Satellite cells were maintained in RPMI 1640 medium (EuroClone), supplemented with 1% L-glutamine 
(EuroClone), 1% antibiotics (penicillin 100 IU/ml, streptomycin 100 mg/ml, EuroClone) and 15% fetal bovine 
serum (Gibco).
The myogenicity of the cell populations was assessed by immunofluorescence using an antibody against 
desmin (Thermo Fisher Scientific, #PA5-17182), specifically expressed in myogenic cells, and counting the num-
ber of desmin-positive cells. Cultures displaying over 70% myogenic cells were selected for further in vitro exper-
iments. To induce the myogenic differentiation, cells were shifted to RPMI 1640 medium with 5% horse serum 
(EuroClone).
RNA isolation and quantitative Real Time PCR. Total RNA was isolated from muscle specimens and 
cultured cells using the TRIzol reagent method (Invitrogen), according to manufacturers’ protocols. RNA purity 
and concentration were quantified using an UV spectrophotometer (DU 800, Beckman Coulter). The expression 
of selected mRNA and microRNA was analyzed using reverse transcription quantitative real-timePCR (qPCR). 
1 μg of total RNA was reverse-transcribed, using SuperScript III First-Strand Kit (Invitrogen), and subsequently 
quantified with StepOne system (Applied Byosistem), using specific FAM-labelled TaqMan probes (Thermo 
Fisher Scientific) for ACTB, HDAC4, MYOG, MYOD1, MEF2C and PAX7. For the determination of MYF5, 
FGFBP1 and PAX3 transcript levels, we used SybrGreen technology (Life Technologies).
For microRNAs analysis, 10 ng of total RNA was reverse-transcribed, using the TaqMan MicroRNA Reverse 
Transcription kit (Life Technologies), and subsequently quantified using specific FAM-labelled TaqMan probes 
(Thermo Fisher Scientific) for U6, MIR206, MIR155, MIR23A, MIR133A, MIR133B, MIR1, MIR499, MIR208B, 
MIR29C, MIR9 and MIR223.
The FAM-labelled TaqMan probes and the sequences of the primers used in SybrGreen technology are listed in 
Supplementary Table 2. The 2−ΔΔCt method was applied to calculate fold differences in gene expression using the 
housekeeping genes (ACTB and U6, for genes and microRNAs expression, respectively) for data normalization.
Protein extraction and Western Blot analysis. 20–30 mg of frozen tissues were homogenated in 200 
μl modified lysis buffer (25 mM Tris-HCl pH 7.6, 2 mM EDTA pH 8, 250 mM Sucrose, 0.1% TritonX-100, 5 mM 
DTT, 1 mM PMSF, 200 mM SOV4, 10 mM NaF, protease inhibitor cocktail 1X; Sigma-Aldrich). A standard 
RIPA buffer (25 mM Tris-HCl, 1% NP-40, 1% Na-deoxycholate, 150 mM NaCl, 1 mM PMSF, 1 mM NaF, 1 mM 
Na3VO4, protease inhibitor cocktail 1X; Sigma-Aldrich) was instead used for the extraction of total proteins from 
cell cultures. Protein samples were quantified by the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) and 
stored at −20 °C.
20 µg of lysate samples were separated on Mini-PROTEAN TGX Stain-Free Gels (4–20%, Bio-Rad). The gel 
was transferred to a nitrocellulose membrane (Bio-Rad) for 10 min using the Trans-Blot Turbo Transfer System 
(Bio-Rad) with Trans-Blot Turbo Mini Transfer Packs (Bio-Rad). The membrane was activated for 1 minute and 
then incubated with an antibody against HDAC4 (Cell Signaling, #2072) at a dilution of 1:500. Immune com-
plexes were detected using the ChemiDoc Touch Imaging System (Bio-Rad)after incubation with Clarity Western 
Figure 7. Schematic representation of possible therapeutic targets in the skeletal muscle at the neuromuscular 
junction. We identified three muscular microRNAs as potential therapeutic targets in ALS patients. Their 
targeted over-expression in the skeletal muscle could act on several fronts: (1) promote the regeneration process 
of the muscle itself, (2) increase the signals aimed at promoting the re-innervation by the motor neuron and (3) 
lead to a slowdown of the atrophy process by promoting the conversion of the muscle fibres in the more resistant 
slow type.
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ECL Substrate (Bio-Rad). HDAC4 protein expression was quantified and normalized to stain free gel loading 
using ImageLab software (version 5.2.1, Bio-Rad).
Histological analysis. Frozen biopsies were cut into 10 micrometers-thick slices using a cryostat. Sections 
were stained using the following histochemical techniques: hematoxylin and eosin, nicotinamide adenine dinu-
cleotide dehydrogenase tetrazolium reductase and ATPase at pH 4.3, 4.6 and 9.4.An overall number of >1000 
muscle fibres was counted for each assessed biopsy, using the Stereo Investigator system (Stereo Investigator 
software, Version 9). Fibres below 40 micrometers in diameter were considered atrophic.
microRNA mimic treatments. MicroRNA mimicry was performed in primary satellite cell cultures. To 
this aim, cells were plated at a 50% seeding density, andgrownuntil 80–90% confluent. Myogenic induction was 
then initiated by replacing the growth medium with the differentiation medium (see above) for 1 week. The 
MIR206 mimic (Qiagen), was added to medium [50 nM] and transfected in cells using the FuGENE HD transfec-
tion reagent (Promega), at the beginning and after 4 days of myogenic induction. Cells treated only with transfec-
tion reagent (mock) were used as controls. After 1 week, cells were collected and protein and RNA extracted; the 
effects of treatments were then evaluated by qPCR and western blot.
Statistical analysis. Data were analyzed using GraphPad Prism software version 6.0. All data are shown as 
means ± standard deviation (SD). Statistical differences between groups were analyzed using unpaired Student’s 
t-test. Correlations were calculated using the Pearson’s correlation test. All statistics were two-tailed and the level 
of significance was set at P = 0.05.
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